← Back to patent-cliff list
LY-5625574
Tier C — Watch / tradeLY-5625574
Zomagen Biosciences Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：NLRP3
Indications (approved)：心包炎, Cryopyrin蛋白相关周期性综合征, Inflammatory disease
Regional status
US
Phase II
2023-03-18
EU
Phase II
2025-01-28
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of LY-5625574?
Approved indications include: 心包炎, Cryopyrin蛋白相关周期性综合征, Inflammatory disease.
When does the LY-5625574 patent expire?
No public expiry year is available for LY-5625574 yet; this page updates once verified.
How do I get a quote for LY-5625574 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21